Matthew Herper continues to lead the pack in investigating the shenanigans perpetrated by Shering-Plough (SGP) and Merck (MRK)in the conduct of the ENHANCE trial of Vytorin. I reiterate that it is my strong but measured and carefully considered opinion that this drug or ezetimibe should NOT be used in ANY patients until definitive evidence of efficacy is available, since alternative, more proven alternatives exist. Patients' health should not be risked on this drug. There is too much uncertainty, and too many proven alternatives.
Matthew's article describes more intriguing aspects of this saga, and I couldn't state it any better than he, so I invite you to read his article:
http://www.forbes.com/2008/01/10/merck-schering-vytorin-biz-cx_mh_0111enhance.html?partner=email
Type rest of the post here
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.